Koester Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
- Paid Up Capital ₹ 1.50 M
- Company Age 6 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 59.26%
- Profit Growth 192.98%
- Ebitda 151.00%
- Net Worth 79.58%
- Total Assets 70.38%
About Koester Pharmaceuticals
Koester Pharmaceuticals Private Limited (KPPL) is a Private Limited Indian Non-Government Company incorporated in India on 04 September 2018 (Six years and five months 23 days old ). Its registered office is in Kanpur Nagar, Uttar Pradesh, India.
The Corporate was formerly known as Somatic Healthcare Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.50 M, as per Ministry of Corporate Affairs (MCA) records.
Arvind Verma and Aditya Kumar serve as directors at the Company.
Company Details
- Location
Kanpur Nagar, Uttar Pradesh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24304UP2018PTC107417
- Company No.
107417
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Sep 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Koester Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Arvind Verma  | Director | 04-Sep-2018 | Current |
| Aditya Kumar | Director | 12-Jun-2023 | Current |
Financial Performance of Koester Pharmaceuticals.
Koester Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 59.26% increase. The company also saw a substantial improvement in profitability, with a 192.98% increase in profit. The company's net worth Soared by an impressive increase of 79.58%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Koester Pharmaceuticals?
In 2023, Koester Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Koester Pharmaceuticals?
Koester Pharmaceuticals has a workforce of 21 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Koester Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Koester Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
